AstraZeneca, US and R&D
AstraZeneca invests $3.5B in US manfacturing, R&D
The company is also raising its full-year guidance to $14.9 billion in adjusted EBITDA, an 8.8% increase from its last projection. The U.S. is AstraZeneca’s largest market, generating 44% of its total revenue, according to its Q3 earnings presentation.
Pharma Giant AstraZeneca Takes China Probes
AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...
AstraZeneca on Tuesday revealed that it’s adding $2 billion more to its current outlay in the U.S., representing a total ...
Recent health news highlights include Amgen addressing bone density concerns, AstraZeneca revising its financial outlook ...
AstraZeneca Pharma India on Wednesday said its net profit declined by 27 per cent on-year to Rs 38 crore in the second ...
Despite China’s investigations into insurance fraud, allegedly illegal importation of unapproved drugs and improper ...
Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...
If requested, AstraZeneca will fully cooperate with the Chinese authorities. On Tuesday, the European pharma giant ...
Hosted on MSN10h
AstraZeneca Q2 net profit declines 10%, revenue up 31%Mumbai: AstraZeneca Pharma India Ltd posted a profit after tax of ₹51 crore, down 10% year-on-year, in the September ...
AstraZeneca Pharma India's net profit for Q2 FY25 declined 27% to Rs 38 crore, while revenue rose to Rs 408 crore. The company's shares closed 3.74% lower on the BSE.
AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback